Carbamazepine

Historical note and nomenclature
Article section 1 of 12.  Next

By K K Jain MD

Carbamazepine is classified as an antiepileptic drug, although it is used for other indications as well. The era of antiepileptic drugs started with the introduction of bromides in 1857 and was followed by the discovery of the anticonvulsant effect of barbiturates in 1912 (Hauptman 1912) and then by hydantoins a few years later (Werdnecke 1916). Several years elapsed without any further drug development in this area when, during the development of the antidepressant drug imipramine, carbamazepine (a related compound) was synthesized and shown to have antiepileptic properties (Schindler and Hafliger 1954). Efficacy in treating epilepsy was demonstrated by clinical trials (Lustig 1964). The beneficial effect of carbamazepine on trigeminal neuralgia was also demonstrated (Blom 1962). The compound was developed and introduced into clinical practice as an antiepileptic drug in 1963 in the United Kingdom and Switzerland. It was initially used in the 1960s for the treatment of trigeminal neuralgia in the United States and was approved later for the treatment of epilepsy. Classical reviews of carbamazepine include 2 monographs (Sillanpaa 1981; Kramer and Hopf 1987).

In This Article

Historical note and nomenclature
Pharmacology
Clinical trials
Indications
Contraindications
Goals and duration of treatment
Dosing
Precautions and use in special groups
Interactions
Adverse effects
References cited
Contributors